DiaMedica Therapeutics (DMAC) Profit After Tax (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Profit After Tax of -$10.0 million for Q1 2026, down 30.3% year-over-year from -$14.4 million in Q1 2025, and down 14.1% quarter-over-quarter from -$8.8 million in Q4 2025.
DiaMedica Therapeutics (DMAC) Profit After Tax (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Profit After Tax history runs 9 years deep, the most recent figure standing at -$10.0 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 30.3% year-over-year to -$10.0 million; the TTM figure through Mar 2026 stood at -$35.1 million (down 30.71% YoY), while the FY2025 annual figure was -$32.8 million, down 34.28% from the prior year.
- Profit After Tax for Q1 2026 stood at -$10.0 million, down from -$8.8 million in the prior quarter.
- The five-year high for Profit After Tax was -$3.1 million in Q3 2022, with the low at -$10.0 million in Q1 2026.
- The 5-year median for Profit After Tax is -$5.2 million (2024), against an average of -$5.9 million.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax gained 11.48% in 2022, then tumbled 56.78% in 2024.
- DiaMedica Therapeutics' Profit After Tax stood at -$3.8 million in 2022, then slumped by 34.04% to -$5.0 million in 2023, then plunged by 56.78% to -$7.9 million in 2024, then decreased by 11.65% to -$8.8 million in 2025, then retreated by 14.1% to -$10.0 million in 2026.
- Business Quant data shows DMAC's Profit After Tax at -$10.0 million in Q1 2026, -$8.8 million in Q4 2025, and -$8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | -10.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.15 Mn |
| Mar 31, 2026 | -10.04 Mn |
| Dec 31, 2025 | -8.80 Mn |
| Sep 30, 2025 | -8.56 Mn |
| Jun 30, 2025 | -7.70 Mn |
| Mar 31, 2025 | -7.71 Mn |
| Dec 31, 2024 | -7.88 Mn |
| Sep 30, 2024 | -6.14 Mn |
| Jun 30, 2024 | -5.12 Mn |
| Mar 31, 2024 | -5.15 Mn |
| Dec 31, 2023 | -5.03 Mn |
| Sep 30, 2023 | -4.54 Mn |
| Jun 30, 2023 | -4.48 Mn |
| Mar 31, 2023 | -5.27 Mn |
| Dec 31, 2022 | -3.75 Mn |
| Sep 30, 2022 | -3.05 Mn |
| Jun 30, 2022 | -3.36 Mn |
| Mar 31, 2022 | -3.51 Mn |
| Dec 31, 2021 | -3.25 Mn |
| Sep 30, 2021 | -3.45 Mn |